Note: Descriptions are shown in the official language in which they were submitted.
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/028~4
CONTINUOUS MICROSPHER~ PROCESS
Background of the Invention
Microcapsules and Microspheres formed from various
natural and synthetic polymers and resins have become
popular delivery vehicles for various active agents such as
drugs, diagnostic reagents and the like. Degradable
microcapsules and microspheres are of particular interest
for use in so called "depot" formulations, where delivery
of the active agent over.an extended period of time is
desired. Despite the growing number of uses of
microcapsules and microspheres, there remains a need for an
economic and reliable method for their manufacture that
avoids the most significant wastes and expenses associated
with existing methods, while simultaneously providing
products having the most desirable properties.
Processes for preparing microspheres typically involve
the formation of at least one dispersed phase in a
continuous phase. The dispersed phase typically includes
the active agent and polymer and, upon solidification in
the continuous phase, becomes a microsphere. Microcapsules
are similarly formed using multiple phases. In a typical
practice, a water-oil-water (w/o/w) emulsion is formed, and
the polymer caused to precipitate out of one phase onto the
surface of a dispersed phase to form a capsule wall thereon
upon solidification of the polymer.
One difficulty with current processes is their
inability to efficiently produce small particles that
exhibit all of the desired properties of drug
incorporation, low residual solvent and scalability. When
microspheres are intended for subcutaneous, intramuscular
or intravenous delivery, small particles are required.
However, obtaining small particles typically requires a
continuous phase having a high surfactant concentration
and/or viscosity of the continuous phase, and/or a low
viscosity dispersed phase. This can necessitate adjusting
the viscosity and increases the energy input needed for
small particles, thereby further complicating the process.
Moreover, it is often necessary to use a highly viscous
CA 02278744 1999-07-21
W0~98/35654 PCT/US98/02874
dispersed phase in order to obtain higher drug loads.
However, it is extremely difficult to obtain small
particles with a highly viscous dispersed phase. rioreover,
the stirring required to obtain the desired particle sizes
frequently results in excessive foaming, especially when
increased surfactant concentrations or lower viscosity
continuous phases are used. This is problematic in many
systems because, while cooling the system will increase the
viscosity and help to stabilize the droplets and reduce
foaming, the viscosity of the DP will tend to increase more
dramatically than, for example, a typically aqueous
continuous phase. This will make it more difficult to
obtain small droplets. Still further, if the concentration
of the drug is close to the solubility limit of the
dispersed phase solution, the drug could crystalize out of
the system, which can result in low drug incorporation and
burst problems in the release profile.
In many cases, foaming will make it impossible to
obtain the desired particle size. In other cases, the
dispersed phase droplets will escape the mixing zone and
will result in larger particles and an unacceptable
particle size distribution. In still other cases, a
suitable particle size might be achieved, but drug load is
inefficient, which can render the process commercially
unviable.
Another problem encountered with existing processes
occurs in scale up. Once one obtains a batch of
microspheres or microcapsules having the desired
characteristics, such as particle size, drug load, release
profile and the like, it is then necessary to scale up the
process for commercial production. Scaling up to
commercial production typically involves several
successively larger production runs, with various process
parameters changing with each successive scale up. A great
deal of experimentation can be necessary to finally obtain
a commercial scale batch having the characteristics of the
initial run. when a single gram of some of today's more
2
CA 02278744 1999-07-21
WO 98/35654 PCTIUS98/02874
exotic drugs can cost many thousands of dollars, having to
experiment at each successive level of scale up can be
extremely expensive. Likewise, the time and capital
expense associated with the scale up of such processes can
put one at a significant competitive disadvantage.
There is a need for a process that can efficiently
produce small particle sizes with good drug loading in a
continuous manner. The process must be easily adapted to
a wide variety of active agents and polymers, enable
economic and efficient scale up to commercial production
and produce uniform products throughout a given production
run.
Disclosure of the Invention
The present invention is directed to a continuous
process for producing active agent containing polymer
bodies, and more particularly microspheres. The
microspheres produced according to the inventive process
are ideal for carrying drugs, diagnostic reagents, or
various other active agents. Not only is the inventive
process continuous, it also provides a simple, economic and
efficient means of scaling up from a test batch to full
production while maintaining a product having uniform
characteristics throughout the production cycle. No
successively larger batches are required to scale up. Once
a desired formulation is achieved on a small scale, one
need only run the process for a longer period of time in
order to obtain any desired batch size. Advantageously,
the microspheres produced throughout the process have
excellent uniformity.
Moreover, foaming can be 'minimized or entirely
eliminated in the practice of the inventive process,
without having to increase the viscosity of the continuous
phase. Small particle sizes having high drug loads and low
residual solvent concentrations are easily obtained in the
inventive process, even when it is necessary to employ a
viscous dispersed phase. It is extremely difficult, if not
3
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/02874
impossible, to obtain useful small particles with a highly
viscous dispersed phase using current processes. The
inventive process advantageously provides a great deal of
flexibility in adjusting various parameters such as size,
without jeopardizing loading efficiency, yield or
uniformity, which enables use of the microspheres of the
invention in a wide variety of delivery methods. For
example, one advantage of the preferred embodiment is that
mixing intensity can be adjusted independently of the flow
rates of either or both'of the dispersed and continuous
phases, which provides significant flexibility.
Accordingly, it is an aspect of the invention to
provide a continuous method of making active agent
containing polymer bodies comprising forming a dispersed
phase comprising active agent and polymer; providing a
continuous phase in which said dispersed phase will form an
emulsion; continuously introducing.dispersed phase into a
reactor vessel at a dispersed phase feed rate, and
continuous phase into said reactor vessel at a continuous
phase feed rate, said reactor vessel including means for
forming an emulsion, and forming an emulsion of said
dispersed phase in said continuous phase; and finally,
continuously transporting said emulsion from said reactor
vessel to a solvent removal vessel to remove solvent.
In one aspect of the invention the dispersed phase is
fed to said reaction vessel at a rate of from about 4
ml/min to about 400 ml/min, and said continuous phase is
fed to said reactor vessel at a rate of from about 1000
ml/min. to about 20, 000 ml/min. In a preferred embodiment,
the dispersed phase includes a hydrophilic peptide active
agent and a copolymer of lactide and glycolide, and the
process comprises emulsifying the dispersed and continuous
phases in a manner effective to provide an average particle
size of from about 5 ~Cm to about 40 ~,m, and an active agent
load of at least about 9%. Still more preferably, the
average particle size of from about 5 ~,m to about 40 ~cm,
and the active agent load is at least about 15%.
4
CA 02278744 1999-07-21
W0~98/35654 PCT/US98/028"!4
In one embodiment the continuous phase and dispersed
phase are introduced into the reactor in a ratio of from
5:1 to 500:1. More preferably, the continuous phase and
dispersed phase are introduced into the reactor in a ratio
of from 40:1 to 200:1 and, more preferably still about
. 80:1. Preferably, the method comprises emulsifying said
dispersed and continuous phases in a manner adapted to
cause solidification of said dispersed phase polymer within
about 10 seconds. Still more preferably solidification
occurs within about 5 seconds. In one aspect of the
invention, the means for forming an emulsion produces a
mixing zone effective to cause solidification of dispersed
phase polymer within about 10 seconds, and said dispersed
phase is introduced into said reaction vessel in said
mixing zone.
In a preferred aspect of the method the means for
forming an emulsion comprises an impeller. In one
embodiment, the method comprises forming said emulsion by
running said impeller in excess of about 5,000 revolutions
per minute. In another embodiment, the impeller is run at
from about 6,000 to about 10,000 revolutions per minute.
It is another aspect of the invention that the diameter of
said impeller define a diameter of a cylindrical zone
extending axially from said impeller, and said dispersed
phase is introduced into said axially extending zone.
In one embodiment the dispersed phase is a homogeneous
solution. In another embodiment the dispersed phase is an
emulsion. In a preferred embodiment the average residence
time of said dispersed phase in said reactor is less than
about 5 seconds.
It is another aspect of the invention that the method
steps are carried out for a period sufficient to produce a
' desired population of microspheres, and wherein the
microspheres produced at the beginning of said period have
substantially the same size and agent load as microspheres
produced at the end of said period.
It is yet another aspect of the invention to provide
5
CA 02278744 1999-07-21
W0~98/35654 PCT/US98/02874
a method of scaling up the production of active agent
containing polymer bodies from a first population having a
desired average particle size and agent loading, to a
second, larger population having substantially the same
average particle size and agent loading. This embodiment
comprises introducing a continuous phase and a dispersed
phase containing said active agent and polymer into a
reactor vessel, and mixing said phases to form an emulsion
of said dispersed phase in said continuous phase in said
vessel; continuously transferring the emulsion from said
reactor vessel to a solvent removal vessel and removing
solvent from said emulsion therein; obtaining said first
population having said desired average particle size and
agent loading; and, thereafter, selecting a suitable
duratlOIl for continuously performing the first two steps to
produce a desired second larger population of agent
containing polymer bodies, and continuously performing the
first two steps for a period sufficient to obtain said
second population.
In a preferred aspect of this embodiment the desired
average particle size and agent loading in said first
population is obtained by performing the first two steps,
and adjusting at least one parameter selected from the feed
rate of said dispersed phase into said reactor vessel, the
feed rate of said continuous phase into said reactor
vessel, and the intensity by which said continuous and
dispersed phases are mixed, to obtain said desired average
particle size and agent loading.
It is yet another aspect of the invention to provide
microspheres made by the method disclosed herein.
Many additional features, advantages and a fuller
understanding of the invention will be had from the
following detailed description of the preferred embodiments
and accompanying drawing.
Brief Description of the Drawings
rig. 1 is a stylized schematic representation of an
6
CA 02278744 2004-11-15
apparatus useful in carrying out the process of the invention.
Fig. 2 is a stylized representation of a portion of a preferred reactor vessel
according to the invention.
Detailed Description of the Preferred Embodiments
In the preferred process of the invention a dispersed phase includes a
polymer and an active agent. It will be apparent to those of ordinary skill in
the art
in view of the present disclosure that the active agent can be any agent for
which
encapsulation or interspersion within a small polymer body is desired.
Preferably,
the active agent is a drug or diagnostic agent and the microspheres are
intended
for the delivery of such drug or diagnostic agent to a patient in need
thereof. The
preferred drugs may be peptide drugs, proteinaceous drugs, steroidal drugs,
non-
steroidal drugs, simple compounds and so on. A representative list of suitable
drugs and other active agents may be found in U.S. Patent Nos. 5,407,609,
4,767,628, 3,773,919 and 3,755,558. Of particular interest are LH-RH agonists
such as leuprolide, triptorelin, goserelin, nafarelin, historelin and
buserelin, LH-RH
antagonists, somatostatin analogs such as octreotide, human, salmon and eel
calcitonin, growth hormones, growth hormone releasing hormones, growth
hormone releasing peptide, parathyroid hormones and related peptides,
interferon,
erythropoietin, GM-CSF, G-CSF, thymosin, antitrypsin, enterostatin, and
chemotherapy drugs, antibiotics and analgesics for regional administration. An
especially preferred drug for use in the instant invention is leuprolide.
In order to incorporate the active agent into the dispersed phase it is
usually
necessary to dissolve the active agent in a solvent. Solvents for the active
agent
will of course vary depending upon the nature of the agent. Typical solvents
that
may be used in the dispersed phase to dissolve the active agent include water,
methanol, ethanol, dimethyl sulfoxide (DMSO), dimethyl formamide, dimethyl
acetamide, dioxane, tetrahydrofuran (THF) , methylene chloride, ethylene
chloride,
carbon tetrachloride, chloroform, lower alkyl ethers such diethyl ether and
methyl
ethyl ether, hexane, cyclohexane, benzene, acetone, ethyl acetate, and the
like.
Selection of suitable solvents for a given system will be within the skill in
the art
7
CA 02278744 2004-11-15
in view of the instant disclosure.
Polymers useful in the present invention can also vary. Examples of
polymers known to those of ordinary skill in the art, and useful in the
present
invention, may be found in, for example, U.S. Patent Nos. 4,818,542,
4,767,628,
3,773,919, 3,755,558 and 5,407,609. In selecting a particularly desirable
polymer
for a given system, numerous factors can be considered for purposes of
producing
a product having the desired clinical characteristics such as biodegradability
(e.g.,
release profile) and biocompatibility. Once one of ordinary skill in the art
has
selected a group of polymers that will provide the desired clinical
characteristics,
then the polymers can be evaluated for desirable characteristics that will
optimize
the manufacturing process. For example, in some instances, it may be possible
to
select a polymer that will interact with the active agent in a manner that
will
facilitate the processing of the microspheres, enhance drug load, enhance
solvent
removal from the dispersed phase or inhibit drug migration from the dispersed
phase into the continuous phase.
One consideration in selecting a preferred polymer is the hydro-
philicitylhydrophobicity of the polymer. Both polymers and active agents may
be
hydrophobic or hydrophilic. Where possible it is desirable to select a
hydrophilic polymer for use with a hydrophilic active agent, and a hydrophobic
polymer for use with a hydrophobic active agent. In the preferred LH-RH
microspheres, an ionic interaction between the drug and the hydrophilic
8
CA 02278744 1999-07-21
WU 98/35b54 PCTNS98/02874
carboxyl groups of the polymer is believed to enhance the
drug load. In general, however, since hydrophilic drugs
are soluble in water, if there is no affinity between the
, polymer and drug, or solidification is not sufficiently
fast, drug load may decrease. It is also possible to use
a hydrophilic drug in a hydrophobic polymer.
In selecting a particular polymer, the effect of the
hydrophobicity/hydrophilicity of the polymer on the
residual solvent in the system should also be considered.
A hydrophilic polymer can he expected to yield low residual
solvent with a hydrophilic drug, such as a hydrophilic
peptide. In the case of the preferred leuprolide
microspheres, the drug has a tendency to help eliminate
hydrophobic solvent from the dispersed phase droplets
quickly and efficiently. In addition, it has been observed
that a greater drug load tends to correlate to lower
residual solvent concentrations. Thus, in some systems,
there is an indirect benefit with lower residual solvent
when incorporating hydrophilic drugs in hydrophilic
polymers. However, since there are other influencing
factors on residual solvent other than hydrophilicity, this
effect may not uniformly apply to non-peptide drugs.
Plevertheless, it should follow that active agents that
enhance the elimination of solvent from the dispersed phase
droplet, without concomitant drug loss, yield superior
products.
Another consideration is molecular weight of the
polymer. While the molecular weight of the polymers will
obviously impact on the product characteristics such as
release rate, release profile and the like, it can also
impact the process of producing the microspheres. Higher
molecular weight polymers are typically associated with a
more viscous dispersed phase, resulting in larger particles
or increased difficulties in obtaining small particles and,
in some instances, increased residual solvent. By
contrast, lower molecular weight polymers are typically
associated with slower solidification because the polymer
9
CA 02278744 1999-07-21
W0~98/35654 PCT/US98/02874
tends to be more soluble. In the preferred system, higher
residual solvent, higher drug loading and enhanced
incorporation efficiency has been found to result from the
use of higher molecular weight polymers. One advantage of
the inventive process is its ability to form good, small,
low residual solvent microspheres with high molecular
weight polymers and, hence, viscous dispersed phases. of
course, the particular selection will also depend upon the
desired product characteristics. For example, the higher
the molecular weight, the longer the degradation time in
the body and the longer the duration of drug release.
Still further, the particular polymer concentration
employed can effect the system, not only from a product
morphology standpoint, but also from a processing
standpoint. An increase in polymer concentration tends to
be associated with a higher drug load because a viscous
dispersed phase needs to eliminate less solvent for
solidification. An increased solidification rate tends to
cause higher drug retention. Moreover, a viscous dispersed
phase leads to less drug diffusion into the continuous
phase during solidification. In some systems this may also
result in higher residual solvent. In the preferred
embodiments, polymer concentration in the dispersed phase
will be from about 5 to about 400, and still more
preferably from about a to about 300.
Especially preferred polymers are homopolymers of
lactic acid, or copolymers of lactic acid and glyco~lic
acid, i.e., poly(lactide-co-glycolide) or "PLGA" polymers.
The ratio of lactic acid residues to glycolic acid residues
can vary, and will typically range from 25:75 to 75:25,
although even a 10% glycolide could find use since high
lactide content results in lower viscosity and higher
solubility. Preferred copolymers comprise at least about
50% lactic acid residues, such as 50:50 or 75:25 polymers.
Poly(lactide-co-glycolide) copolymers are commercially
available from a number of sources and can be readily
prepared by conventional synthetic routes. Boeringer
CA 02278744 2004-11-15
Inglehiem produces suitable polymers under the designations RG 502, RG 502H,
RG 503, RG 503H, RG 752, RG 756 and others. With the preferred LH-RH
microspheres RG502H and RG503H are used in the dispersed phase in
concentrations of 23% and 13% respectively. Such copolymers also may be made
by polymerizing lactic acid and glycolic acid or, preferably, by polymerizing
the
cyclic dimers of lactic acid and glycolic acid, namely lactide and glycolide,
as
described in, for example, U.S. patent number 3,773,919. Selection of a
suitable
polymer for a given system would be apparent to those of ordinary skill in the
art
in view of this disclosure.
Solvents for the polymer will also vary depending upon a number of factors,
including the nature of the polymer, the active agent, toxicity, compatibility
with
other solvents in the system and even the use to which the microsphere will be
put. Thus, in addition to dissolving the polymer, the solvent must be
immiscible
with the continuous phase in order to form droplets, highly volatile for
optimum
evaporation efficiency, and desirably nonflammable for safety reasons.
Solvents
suitable forthe preferred poly(lactic) or poly(lactide-co-glycolide) polymers
include
methylene chloride, chloroform, ethyl acetate, substituted pyrrolidone and the
like.
In some instances, the solvent for the active agent will be the same as the
solvent
for the polymer. Some drugs, typically diagnostic agents such as radioactive
inorganic salts used in imaging analysis, are not soluble or only slightly
soluble in
organic solvents. In these instances, a fine, sub-sub micron size powder can
be
directly suspended in the polymer solution to form microspheres. Although
resort
to this will be rare in drug delivery, it may prove useful with diagnostic
agents.
Selection of other solvents useful in accordance with the process of the
invention
will be within the skill in the art in view of the instant disclosure.
The polymer, active agent and solvent or solvents are
11
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/02874
combined to form the dispersed phase. In the preferred
embodiment, the dispersed phase is a true, homogeneous
solution which may be prepared by mixing the polymer,
solvent and active agent together to form a solution.
Alternatively, separate solutions of polymer and active
agent can be prepared, each in its own solvent, and
subsequently mixed to form the dispersed. phase solution.
In some instances, due to the nature of the active agent
and/or polymer, the dispersed phase must be formed as an
emulsion. For example, when a given proteinaceous drug is
dissolved in a suitable active agent solvent, the resulting
solution may be completely immiscible with a solution of
the polymer in a particular polymer solvent. In order to
provide a relatively homogeneous dispersed phase in which
the drug and polymer are relatively uniformly interspersed,
the drug and drug solvent may be emulsified caith the
polymer and polymer solvent to form a dispersed phase
emulsion. Upon introduction of the dispersed phase into
the continuous phase a w/o/w emulsion is formed. In still
other systems, the dispersed phase can be prepared by
forming a direct suspension of the active agent in a
polymer solution.
In accordance with the inventive process described
below, the dispersed phase heretofore described is
dispersed or emulsified in a continuous phase in order to
form droplets or inclusions of dispersed phase in the
continuous phase. As used herein the terms emulsified or
dispersed are intended in their broadest sense as meaning
discrete regions of dispersed phase interspersed within the
continuous phase. The noted inclusions will typically
occur as generally spherical droplets, but may in some
instances be irregular inclusions due to particular
emulsification conditions. Any suitable medium in which
the dispersed phase will farm droplets or inclusions may be
used as a continuous phase, with those that provide a
maximum solvent sink for the dispersed phase solvent being
especially desirable. Frequently, the continuous phase
12
CA 02278744 2004-11-15
will also contain surfactant, stabilizers, salts or other additives that
modify or effect
the emulsification process. Typical surtactants include sodium dodecyl
sulphate,
dioctyl sodium sulfo succinate, span~, polysorbate 80, tween~ 80, pluronics~
and
the like. Particular stabilizers include talc, PVA and colloidal magnesium
hydroxide. Viscosity boosters include polyacrylamide, carboxymethyl cellulose,
hydroxymethyl cellulose, methyl cellulose and the like. Buffer salts can be
used
as drug stabilizers and even common salt can be used do help prevent migration
of the active agent into the continuous phase. One problem associated with
salt
saturation of the continuous phase is that PVA and other stabilizers may have
a
tendency to precipitate as solids from the continuous phase. In such instances
a
particulate stabilizer might be used. Suitable salts, such as sodium chloride,
sodium sulfate and the like, and other additives would be apparent to those of
ordinary skill in the art in view of the instant disclosure.
In the preferred embodiment, the continuous phase is water. The aqueous
continuous phase will typically include a stabilizer. A preferred stabilizer
is
polyvinyl alcohol (PVA) in an amount of from about 0.1 °~6 to about
5.0°~6. Still more
preferably, PVA is present in an amount of about 0.35%. Other stabilizers
suitable
for use in the continuous phase would be apparent to those of ordinary skill
in the
art in view of the instant disclosure.
The selection of particular polymers, solvents and continuous phases will
of course vary depending on the active agent and the desired product
characteristics. Once the desired product characteristics, such as clinical
application, release profile and the like are established, there may
nevertheless
be some latitude in selecting polymers, solvents and continuous phases to
facilitate the production process.
For example, in slow solidifying systems, or systems where small
particles are desired, a viscous continuous
13
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/02874
phase and a higher concentration of stabilizer may be
necessary to obtain the desired microspheres. Likewise, if
necessary, the dispersed phase can be made more viscous by
cooling, increasing the molecular weight of the polymer or
increasing the concentration of the polymer. Of course,
adjusting the viscosity of the continuous phase further
complicates the process, and use of a dispersed phase with
a high viscosity makes it more difficult to obtain small
particles. Still further, in addition to complicating both
the process and apparatus; cooling the viscous phase will
have a tendency to reduce the solubility of the dispersed
phase solvent therein, which can lead to higher residual
solvent contents and/or longer solvent removal periods.
Drug crystallization might also be a problem with cooling.
An advantage of the preferred embodiment of the invention
is that, because foaming is not a significant impediment,
it is not necessary to cool or otherwise adjust the
viscosity of the phases in order to obtain small particle
sizes. The present process enables one to obtain small
particle sizes even when it is necessary to use a viscous
dispersed phase, without having to adjust the viscosity of
the continuous phase to prevent foaming. This simplifies
the process and reduces costs.
In carrying out the process, once the dispersed and
continuous phases are prepared, they are fed to a reaction
vessel in which the dispersed phase is interspersed or
emulsified to form droplets or inclusions in the continuous
phase as described below.
Referring to Fig. 1, the process is commenced after
the reaction vessel 10 is primed with a suitable starting
volume of continuous phase from continuous phase reservoir
12. In the case of, for example, a 90 mL reactor vessel
10, the starting volume will be on the order of about 70
mL. of course, the actual starting or priming volume will
depend on the size and configuration of the reactor vessel,
the location of the harvest line 20 and, in the case of a
closed reactor vessel, the minimum amount of head space
14
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/02874
needed to control foaming. Those of ordinary skill in the
art can empirically select the suitable priming volume for
any given system.
The reactor vessel 10 may be open or closed, and is
preferably closed. Fluids are advantageously moved through
the closed system by the pumping action of the mixer. In
addition, a closed reaction vessel also reduces the
potential for foaming problems. A preferred vessel l0 is
commercially available from Silverson Machines Inc.,
designated as in-line mixer assembly for L4R/L4RT. In
order to implement the advantageous features of the
inventive process, the noted apparatus was modified to add
a second inlet port for the dispersed phase as described in
more detail below. The inlet tube had a diameter of
approximately 1/5 to 1/lOth the diameter of the inlet tube
that comes with the apparatus. The tube tip was positioned
approximately 1/4 inch below the stirrer head.
Once reactor 10 is primed, continuous phase is pumped
or drawn into reactor 10 via continuous phase feed line 16,
and dispersed phase is simultaneously pumped or drawn into
reactor 10 via dispersed phase feed line 18 from dispersed
phase reservoir 13. In the case of an open reactor the
continuous phase emulsion is continuously pumped or drawn
from reactor 10 via harvest line 20 into solvent
evaporation tank 22. In the preferred closed reactor 10,
formed or forming microspheres are pumped from vessel 10
for subsequent processing by the action of the mixer. on
a small pilot scale the dispersed phase is stored in a
small, for example, 125 mL addition funnel, which is
pressurized to feed into the reactor vessel. Continuous
phase is retained in a large reservoir, but in large scale
production both phases (fluids) can be contained in
standard stainless steel pressure tanks. Thereafter, a
metering valve in the continuous phase addition line can
control the flow of continuous phase from the pressurized
tank. Alternatively, for smaller scale apparatus,
continuous phase can be pumped into the reactor from an
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/(12874
unpressurized vessel using a calibrated peristaltic pump.
The flow rate of the dispersed phase from, for example a
pressurized glass or stainless steel vessel, can be
uniformly controlled using a pre-calibrated micrometer
needle valve. For large scale production valueless
metering pump-dispensers from a non-pressurized tank might
be used.
Two important aspects of the process of the invention
involve the introduction of the dispersed phase and
continuous phase into vessel 10. First, the ratio of the
dispersed phase to the continuous phase, which can effect
solidification rate, active agent load, the efficiency of
solvent removal from the dispersed phase, and porosity of
the final product, is advantageously and easily controlled
by controlling the flow rate of the dispersed and
continuous phases into vessel 10 via feed lines 16 and 18.
Second, the droplet size, solidification rate and
efficiency of solvent removal are also effected by where
the dispersed phase is introduced into reactor 10 relative
to the emulsification device. Each of these aspects of the
invention are discussed in more detail below.
First, as noted, the ratio of dispersed phase to
continuous phase effects the rate of solidification, the
drug load and, importantly, the. amount of residual solvent
in the microsphere. At a minimum there must be enough
continuous phase relative to dispersed phase solvent to
create a sink for the dispersed phase solvent. Thus, as a
minimum, the amount of continuous phase must be greater
than the solubility limit of the dispersed phase solvent in
the continuous phase. The maximum ratio of dispersed phase
to continuous phase will be limited by the physical size of
the apparatus used, the desired amount of head space, the
size of the evaporation tank and the like. The general
rule is that by increasing the amount of continuous phase,
one creates a greater sink for the dispersed phase solvent.
In addition, increasing the amount of head space in
conjunction with an air sweep or other means of replacing
16
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/02874
ar removing air/vapor from above the surface of the -
continuous phase can also enhance the sink nature of the
continuous phase. In practice, this will be preferably
done in a solvent removal tank and not in the reactor.
In between the maximum and minimum desired amounts of
continuous phase to dispersed phase, the present process
provides a great deal of flexibility in controlling and
adjusting the ratio while simultaneously allowing the
process to be run in a continuous manner. Advantageously,
in the continuous process' of the invention the ratio of
dispersed phase to continuous phase can be easily
controlled by controlling the feed rate of each to the
reactor vessel. This in turn is easily and accurately
accomplished using commercially available flow regulators,
such as turbine, paddle wheel, gear-type, positive
displacement or magnetic flowmeters, or valueless metering
pumps or similar apparatus apparent to those of ordinary
skill in the art. A unique benefit of the instant
invention is that the ratio of dispersed phase to
continuous phase can be constantly maintained throughout
the entire process, which enables the consistent production
of uniform microspheres throughout the entire duration of
a given production run.
The actual ratios of continuous phase to dispersed
phase will depend upon the desired product, the polymer,
the drug, the solvents, etc., and can be determined
empirically by those of ordinary skill in the art. In the
preferred embodiment, the ratio of continuous phase to
dispersed phase will typically range from about 5:1 to
about 500:1, and more preferably about 40:1 to about 200:1.
In the preferred LH-RH system the optimal ratio is about
80:1. This translates into flow rates for the dispersed
' phase of from about 1000 mL/min. to about 5 mL/min., more
preferably from about 40 mL/min. to about 12 mL/min, and
still more preferably about 25 mL/min., with a continuous
phase flow rate fixed at 2000 mL/min. If the continuous
phase flow rate is increased, the dispersed phase flow rate
17
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/OZ874
will change accordingly. On a production scale the
continuous phase flow rate may be as high as 20,000
mL/minute in order to reduce the processing time. In the
preferred process of making LH-RH microspheres, the flow
rate of continuous phase will be on the order of about 2000
ml/min. and the flow rate of dispersed phase will be on the
order of about 25 ml/min.
As shown in Fig. 1, the continuous phase feed line 1G
is substantially larger than the dispersed phase feed line
18 in order to accommodate'the significantly larger volume
of continuous phase used. The flow rate of the dispersed
and continuous phases can be controlled by pumps and flow
regulators, such as the calibrated peristaltic pump and
metering needle valve noted above. As shown, the CP and DP
can be pumped into the reactor vessel 10 by pumps 24.
Alternatively, they can be drawn into the vessel by vacuum
or by the pumping action of the mixer, and their flow rates
controlled by various flow regulators. Likewise, the
continuous phase emulsion can be pumped from the reactor 10
to the solvent evaporation tank 22 by pump 26, in the case
of an open reactor system, or by the pumping action of the
impeller in a closed system. on a bench scale apparatus,
the continuous phase pump 24 can be a simple peristaltic
pump. However, due to the pressure head above the
dispersed phase, use of a peristaltic pump is difficult for
delivering the dispersed phase to the vessel 10. Of
course, this problem is reduced or eliminated if a less
volatile solvent is used. After forming the emulsion in
reactor vessel 10, the continuous phase emulsion is easily
drawn or pumped from the reactor vessel l0 into the solvent
evaporation tank 22. of course, depending on the specific
apparatus used it may still be necessary to employ pumps in
continuous phase and dispersed phase feed lines 16,18, and
at the very least flow regulators. Selection of suitable
pumps, flow regulators and the like will be well within the
skill in the art in view of the instant disclosure.
As noted above, placement of the continuous phase and
18
CA 02278744 1999-07-21
WO~ 98/35654 PCT/US98/02874
dispersed phase feed lines 1G, la, can be extremely
important, irrespective of whether reaction vessel 10 is
open or closed. In particular, it is desirable to have the
dispersed phase enter vessel 10 in the optimum zone for
formation of microspheres having the desired
characteristics.
While not wanting to be bound by theory, an advantage
of the present invention is believed to be derived from the
use of exceptionally high intensity emulsification. ny
mechanically mixing the dispersed and continuous phases
under high shear forces or high turbulence, the rate of
solvent removal from the dispersed phase is believed to be
increased. Presumably this is because the increased mixing
intensity causes the dispersed phase to interact with more
continuous phase per unit time. An increased rate of
solvent removal from the dispersed phase to the continuous
phase tends to increase the rate of solidification of the
dispersed phase. wen in those instances where, due to the
polymer, solvents and/or continuous phase used, the
dispersed phase inherently solidifies slowly, the increased
shear or turbulence induced by the increased mixing
intensity associated with the preferred embodiment should
provide an enhanced solvent removal effect and hence, an
advantageously increased solidification rate and reduced
residual solvent content.
High intensity mixing according to the invention is
also believed to advantageously effect the size and agent
loading of the microspheres. Because of the high shear
and/or high turbulence associated with the inventive
process, the dispersed phase is forced to form smaller
aggregates or droplets. Moreover, fast solidification
helps prevent the migration of drug from the dispersed
phase, and impedes the ability of the dispersed phase to
aggregate into progressively larger droplets. As such, it
is possible to obtain very small microspheres having
advantageously high drug loading. Assuming the drug is
adequately phobic to the continuous phase, such as by the
19
CA 02278744 1999-07-21
WO 98/35654 PGT/US98/02874
nature of the drug, additives to the CP or the like, or
because the drug has enhanced affinity for the polymer or
the like, the prompt solidification associated with the
high intensity emulsification of the invention can provide
very small microspheres having excellent drug loading. The
mixing intensity and microsphere sizes associated with the
present invention are achieved without serious foaming
problems or having to further complicate the process by
taking steps to compensate for foaming. Moreover, small
microspheres can be achieved even when it is necessary or
desirable to employ a more viscous dispersed phase.
While increased mixing intensity is desirable in
accordance with the invention, true shear as between two
surfaces, such as an impeller blade and emulsor or stator
screen, can also adversely effect the resultant
microspheres. For example, where the dispersed phase is
introduced directly into a high shear zone, such as the gap
between the impeller and screen, the microspheres may
solidify so quickly and be subjected to such intense shear
forces as to .become elongated and misshaped, rather than
spherical as is preferred. Accordingly, placement of the
feed lines, in particular the dispersed phase feed, can
significantly effect the process. By properly locating the
introduction of the dispersed phase into the vessel 10, one
can ensure the production of uniform spherical particles,
and prompt solidification. In the embodiment shown in Fig.
2, the tip of the dispersed phase feed line 18 need not
physically enter the vessel chamber. As shown, the feed
line can be recessed in channel 19 so that the continuous
and dispersed phases can enter the mixing zone together.
However, it is desirable that the continuous and dispersed
phases not come together too long before entering the
reactor vessel.
In accordance with the invention, the disperse phase
should be introduced into a highly intense mixing zone,
characterized by high shear and/or high' turbulence
effective to cause a high rate of solvent removal from the
CA 02278744 1999-07-21
W0~9$/35654 PCT/US98/02$74
dispersed phase to the continuous phase and, preferably,
corresponding to a high rate of polymer solidification.
However, the dispersed phase should not be introduced into
such high shear forces as to misshape or otherwise
adversely effect the microspheres. The optimum placement
of the feed lines can be determined empirically by those of
ordinary skill in the art based on the instant disclosure
and will obviously vary depending on the particular
apparatus used.
In a preferred embodiment, the high intensity mixing
zone is defined as that in which the dispersed phase
polymer solidifies within about 20 seconds, more preferably
less than about 10 seconds, and still more preferably where
it solidifies in less than about 5 seconds. In the
preferred LH-RH embodiment, the microspheres are solidified
in less than about 3 seconds. Introduction into the
suitable mixing zone can be accomplished by locating the
dispersed phase input line in close proximity to the
emulsification impeller, sonication tip or the like. In a
preferred embodiment, shown in Fig. 1, the emulsification
apparatus includes an impeller 27, and corresponding stator
or emulsor screen 2a. The impeller has a diameter defining
a diameter of a cylindrical zone extending axially from
said impeller and orthoganal the plane of rotation of the
impeller, shown in two dimensions at Z in Fig. 1. In this
embodiment, the dispersed phase is preferably introduced
within the zone Z. More preferably, the dispersed phase is
introduced within the zone Z in close proximity, within
about 20 mm, of the impeller. Still more preferably, the
dispersed phase is introduced about 3 to 10 mm below the
impeller. In the case of the preferred Silverson apparatus
the impeller has a diameter of 32 mm, and the stator screen
a diameter of 34 mm. Thus, in this instance the
cylindrical zone will have a diameter of about 32 mm, and
wherein the most intense shear forces are set up in the two
millimeter gap space between the impeller and stator.
The high turbulence intensity emulsifier may be an
21
CA 02278744 1999-07-21
WO~ 98/35654 PCT/US98/02874
impeller type apparatus, a flow restriction device that -
forces the continuous and dispersed phases through
progressively smaller channels causing highly turbulent
flow, a high frequency sonication tip or similar apparatus
that will be apparent to those of ordinary skill in the art
in view of this disclosure. An advantage of non-static
mixers is that one can control the mixing intensity
independently of the flow rates of the phases into the
device. What is important is that it is capable of
providing adequate mixing'intensity in accordance with the
process of the invention. In the case of the preferred
impeller type apparatus, suitable emulsification intensity
can be obtained by running the impeller in excess of about
5,000 rpm. Preferably, the impeller is run at from about
6,000 to about 10,000 rpm., and most preferably about
7,000. In the case of impeller type devices revolutions
per minute provide a good approximation of adequate mixing
intensity. Of course, the magnitude of the shear forces,
and hence mixing intensity, can also be increased by
adjusting the gap space between the impeller and emulsor
screen or stator. Likewise, the intensity experienced by
the dispersed phase can also be adjusted by properly
locating the feed as discussed above. Commercially
available apparatus adaptable to the instant process
include in-line mixers from Silverson, Ross mixers and the
like. A significant advantage of the preferred embodiment
is that high intensity emulsification, such as that induced
using an impeller at speeds in excess of 5,000 rpm's, can
be employed without creating a foaming problem.
Notably, depending on the active agent, polymer,
solvents, continuous phase, the volume of each, and
numerous other factors, some systems simply will not
solidify rapidly, even when the intensity of mixing is
substantial. In such systems, the most significant
advantages of the inventive process, for example, scale up,
elimination the foaming problem and associated ability to
obtain small particles with good agent loading, product
22
CA 02278744 1999-07-21
WO 98/35554 PCT/US9$/02874
uniformity and the like, are not lost.
Once the emulsion of dispersed phase and continuous
phase is formed, the emulsion is continuously transferred
from the reaction vessel 10 to a solvent removal tank 22.
As used herein, transferring the 'emulsion' may be an
actual emulsion, but in the preferred embodiment will be
more accurately a suspension of solidified dispersed phase
particles suspended in the continuous phase. If
solidification is not especially fast, the emulsion being
transferred may consist df suspension of dispersed phase
droplets in the process of solidifying.
In the case of an open reaction vessel the transfer is
done with one or more pumps. In the case of the preferred
closed reaction vessel the transfer can be done by using
the mixer itself as a pump, or since the solvent
evaporation tank can draw a vacuum, it can be done by
vacuum. Solvent removal is important in the preparation of
microspheres, especially when the resulting microspheres
are intended for clinical applications.
Interestingly, it is observed that in the preferred
system, even though solidification of microspheres is
virtually instantaneous, the formed microspheres are
nevertheless susceptible to give up additional residual
solvent into the continuous phase. Accordingly, it is
believed that some form of solvent evaporation process is
necessary to obtain the desirably low residual solvent
contents necessary for: many clinical applications.
In the solvent evaporation tank the composition is
stirred. Any vessel in which the atmosphere can be
controlled could suffice. Typically, the composition will
be stirred in the solvent evaporation tank for 3 to 8
hours, and in the preferred embodiment about 4. Head space
is preferred to be about 1/3rd the tank capacity. Changing
the air in the head space of the vessel e.g., by replacing
the air with new air, nitrogen or other inert gas, has
proven to be a highly effective means of maximizing solvent
removal. In the preferred embodiment the flow rate is
23
CA 02278744 1999-07-21
W0~98/35654 PCT/US98/02874
about 30 L/min with a 25 liter head space. In this
embodiment, the air in the head space is changed about once
times a minute. Other solvent removal steps suitable for
use in connection with the present invention would be
apparent to those of ordinary skill in the art in view of
the instant disclosure. Thus, increased or infinite
dilution with continuous phase, or replacing solvent
saturated continuous phase with fresh continuous phase, the
use of an air sweep and/or vacuum and the like can be used
to extract additional solvent in the solvent removal tank
after formation of the microspheres. Infinite dilution is
not typically convenient for production level
manufacturing. However, for some products, such as those
sensitive to temperature, it may be useful.
While not wanting to be bound by theory, it is
believed that in the preferred embodiment wherein the
active agent is LH-RH and the polymer is a hydrophilic d,l-
poly(lactide-co-glycolide), solvent removal by evaporation,
which preferably includes an air sweep, is necessary to
obtain the desired degree of solvent removal.
Drug load, in the case of the preferred LH-RH
microspheres, is targeted at 20.5% based on the total
solid. In practice, drug loads on the order of 15 to 19%
can be obtained. Of course, the nature of the drug, the
desired release profile, the nature of the polymer and, of
course, processing can all effect the desired and actual
drug load. In the typical case, drug loads on the order of
5% to 20% based on the combined weight of drug and polymer
are desired and achievable with the process of the
invention.
Advantageously, once the desired drug load is
obtained, and the parameters of feed rate, temperature etc.
are determined, scaling up to larger batches, including
production level batches, becomes a simple matter of
running the process longer. No additional feed tubes,
emulsifiers, impellers or the like are necessary to produce
a larger number of microspheres having the desired
24
CA 02278744 2004-11-15
characteristics. Moreover, the microspheres produced during the continuous
process of the invention are exceptionally uniform in terms of size, agent
load and
the like, regardless of when during the process they were produced.
These and other aspects of the invention will be further understood from the
following non-limiting examples.
Unless otherwise noted the following apparatus was used in the examples.
The Silverson in-line mixer was modified with the additional inlet for the
dispersed
phase as hereinbefore described, and connected to a Silverson stirrer model
4LR.
The outlet tube was connected to a 7 liter jacketed bio-reactor from
Applikon~.
One of the top plate ports of the Applikon was connected to the vacuum pump,
another to a dry 0.2 Nm filter to serve as the air inlet, another served as
the inlet
from the Silverson, and the fourth served as the harvest line.
Example 1
This is an example of a typical procedure used to prepare microspheres of
poly(lactide-co-glycolide) and Leuprolide (LH-RH).
The hydrophilic polymer RG503H is a 50:50 copolymer of poly(lactide-co-
glycolide) from Boehringer Ingelheim having an inherent viscosity of 0.42
dL/g.
This polymer has a weight average molecular weight (Mw) on the order of
30,000. A solution of this polymer was prepared by dissolving 7.0 grams
RG503H in 36 g dichloromethane. The drug solution was prepared separately
by dissolving 1.00 g leuprolide acetate in 8.56 g methanol. The dispersed
phase (DP) was prepared by combining the leuprolide solution and the
polymer solution with mixing. The DP thus formed is a homogeneous light
yellow, relatively clear solution. The DP was then transferred into a 124 mL
pressure addition funnel and connected to the DP inlet to of the Silverson
unit through a micrometer teflon~ needle valve. Head
CA 02278744 1999-07-21
W0~98/35654 PCT/US98/02874
pressure was applied to the addition funnel (10 psi) above
the continuous phase (CP). The stop-cock of the addition
funnel was kept closed until the DP addition started.
The continuous phase (CP) was 0.350 polyvinyl alcohol
(PVA) solution (w/v) prepared in a 7 liter beaker by
dissolving 14.0 g PVA (cold water soluble, MW 30,000-
70,000) in 4000 mL water. The CP addition tube to the
Silverson unit from the CP tank used a peristaltic pump for
flow control. The outlet tube of the Silverson unit was
connected to the solvent"evaporation tank, which is a 7
liter Applikon reactor with a jacketed vessel and lip-seal
stirrer assembly.
The Silverson unit was primed with CP and trapped air
in the cell was removed by opening the bleed valve. The
stirrer motor of the Silverson was turned on to 7000 rpm
and the CP and the DP were introduced into the reactor
simultaneously. The required flow rate of CP and DP were
achieved and maintained constant using the peristaltic pump
(for CP) and needle valve (for DP). The addition time was
2 minutes, during which 52.6 grams of DP and 4000 mL of CP
were introduced to the mixer at a constant rate of flow.
The microspheres were formed in the Silverson unit and
delivered as a suspension into the solvent evaporation
tank. The head space air was constantly replaced using the
vacuum pump. The air flow through the head space was
approximately 29 standard liters per minute. The
temperature of the evaporation tank was increased from 25
to 42C and maintained for 3 hours. The higher temperature
and air sweep helped the system to achieve lower residual
solvent in the microspheres.
After solvent evaporation, the system temperature was
lowered to 25C and the microspheres harvested by pressure
filtration (5-20 psi) onto a 5 ~,m filter using a 2000 mL
stirred cell assembly (M-2000 from Amicon). The
microspheres were washed with 2000 mL WFI and freeze dried
in bulk as a concentrated suspension in WFI (approx. 0.3
g/mL). Of course, this procedure will change upon scale up
26
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/028'74
to commercial production.
The microspheres prepared according to this example
had 9.88% drug load showing 79% drug incorporation
efficiency. Microscope analysis showed that the
microspheres were spherical and the particles ranged from
non-porous to partially porous. Small particles were non-
porous while larger particles showed some porosity. The
bulk density of the microspheres was 0.588 g/cc. The
particle size distribution analysis showed that 50% of the
particles were below 18 ~m (volume distribution), and 800
of the particles were between 7 and 36 ~,m. The residual
solvent (methylene chloride or methanol) was undetectable
(i.e., less than about 20 ppm).
Example 2
As illustrated by this example, a significant
advantage of the preferred continuous flow process
according to the invention is the product consistency
during processing. Prior processes are unable to produce
microspheres having virtually identical characteristics at
the end of the production run as the ones produced at the
beginning and middle of the run. This is a significant
commercial advantage.
The microspheres were prepared in the same manner as
in Example 1, using 25% excess DP and CP. The DP contained
8.75 g RG503H, 1.25 g Leuprolide acetate, 45 g methylene
chloride and 10 . 7 g methanol . The CP was 5000 mL 0 . 35 0
PVA. In this example, the microsphere suspension produced
in the Silverson reactor was not transferred to the solvent
removal tank. Instead, each 1000 mL fraction (the
collection time for each fraction being approx. 24 seconds)
were collected in a 2000 mL beaker. Thus, five fractions
of equal volume was collected. The microspheres from each
fraction were separated by filtration, freeze dried in bulk
- 35 and compared.
Microscopic analysis showed that the morphology of the
microspheres obtained in all five fractions was identical.
27
CA 02278744 1999-07-21
WO 98/35654 PCT/US98/02874
Larger particles showed svme porosity while the smaller
particles were non-porous. The following Table I shows
that each fraction (Frxn) of microspheres produced
throughout the process have excellent consistency.
Table I
Frxn 1 Frxn 2 Frxn 3 Frxn 4 Frxn
5
Load 11.17 11.31 10.96 11.05 10.99
Size (gym)
to l0% under9.G 8.9 , 8.9 9.3 8.9
50% under18.1 17.4 17.8 17.8 17.4
90% under33.3 32.6 35.5 34.4 32.6
Blk DensØ40 0.48 0.48 0.47 0.48
The residual methylene chloride values were higher in
all the fractions (approx. 8000 ppm) because no solvent
evaporation was performed on the microspheres.
Example 3
In this example, a hydrophobic polymer was used.
Boehringer Ingelheim RG502 is a 50:50 co-polymer of PLGA
with an inherent viscosity of 0.2 dl/g. The preparation
procedure was similar to Example l, except for the
composition of the DP. Here, a polymer solution was
prepared by dissolving 8.77 g RG502 in 20 g
dichloromethane. The drug solution was separately prepared
by dissolving 1.25 g leuprolide in 4 g methanol. The
polymer and drug solutions were mixed to form the DP.
Thereafter, 5000 mL of CP was added by adjusting the
micrometer needle valve setting for the DP addition so that
the time for both DP and CP addition was approximately the
same (2 minutes). Silverson stirring, solvent evaporation
and microsphere harvesting were all performed as in Example
1.
The drug incorporation efficiency of the resulting
microspheres was 65% and the microspheres had a drug load
of 8.170 Microscope analysis showed that the microspheres
had spherical geometry and were porous. The bulk density
28
CA 02278744 1999-07-21
W0.98/35654 PCTNS98/02874
of the microspheres was 0.23. The particle size --
distribution analysis showed that 50% of the particles were
below 25.6 ~,m (volume distribution), 80% of the particles
were between 12.2 and 44.0 ~Cm. The residual methylene
chloride and methanol in the microspheres was undetectable
(less than 20 ppm).
Example 4
In this example, a homopolymer of polylactic acid was
used. 8.75 g polylact~c acid (R202H from Doeringer
Ingelheim) having an inherent viscosity of 0.18 dL/g was
dissolved in 20 g dichloromethane. Drug solution was
prepared by dissolving 1.25 g leuprolide in 4 g methanol.
The polymer and the drug solutions were mixed to form the
DP, which appeared as a homogeneous, nearly colorless
solution. The microspheres were prepared and harvested as
disclosed in Example 1 using 5000 mL of continuous phase.
These microspheres had a drug incorporation efficiency
of 85% and a drug load of 10.58%. Microscope analysis
showed that the microspheres had perfect spherical
geometry, with most of the spheres appearing non-porous.
A few of the larger particles appeared to have pores at the
center of the core. The bulk density of the microspheres
was 0.615 g/mL. The particle size analysis showed that 50%
of the particles were below 16.0 um (volume distribution),
and 80% of the particles were between 5.8 and 30.2 ~.m. The
microspheres contained 79 ppm methylene chloride and an
undetectable amount (less than 10 ppm) of methanol.
Example 5
In this example, the microspheres were prepared as in
Example 1 using 8.75 g RG503H, 1.25 g leuprolide, 45 g
methylene chloride and 10.7 g methanol for the DP. The
stirring speed was increased to 9000 rpm, using 5000 mL CP
of Ø35% PVA solution. The drug incorporation efficiency
was 70.7% and the drug load was 8.84% in the microspheres.
Microscope analysis showed that the microspheres were
29
CA 02278744 1999-07-21
WO~ 98/35654 PCT/US98/02874
smaller, had a spherical geometry, and were predominantly
non-porous. The bulk density of the microspheres was 0.510
g/mL. The particle size distribution analysis showed that
50% of the particles fall below 15.5 um (volume
distribution) and 800 of the particles were between 8.1 and
24.8 um. The microspheres contained 47 ppm residual
methylene chloride and an undetectable amount of methanol
(less than l0 ppm).
Example G
In this example, microspheres were prepared containing
a proteinaceous agent. The active agent was the protein
Human Serum Albumin. The microspheres.were prepared by
forming a w/o/w emulsion using RG503H polymer. The
preparation procedure was the same as in Example 1 except
that the dispersed phase was formed by preparing a polymer
solution of 8.75 g polymer in 45 g methylene chloride. 5
mL of 25% w/v solution of human serum albumin was added
slowly into polymer solution while stirring using a
magnetic stirrer. The dispersed phase thus obtained was
stirred vigorously for about 5 minutes to form a milky
white fine suspension. The microspheres were prepared as
in Example 1 except that the stirring speed of the
Silverson unit was 6000 rpm. The microspheres were
harvested and freeze dried as in Example 1.
Microscope analysis showed that the microspheres had
perfectly spherical geometry and were highly porous. The
bulk density of the microspheres was 0.03 g/mL. The
particle size distribution analysis showed that 500 of the
particles were below 48.4 ~,m, and 80% were between 23.0 and
69.7 um. The microspheres did not have any detectible
residual methylene chloride.
Example 7
In this example, microspheres were prepared from
RG503H and a non-peptide drug. The polymer solution was
CA 02278744 1999-07-21
WO 98/35654 PCT/US98I02874
prepared by dissolving 8.74 g RG503H in 45 g
dichloromethane. 1.25 g dipyridamole was added slowly to
the polymer solution and 2.53 g methanol was added to make
the homogeneous solution, which appeared bright yellow.
5000 mL of 0.35% PVA solution was used as the continuous
phase. The microspheres were prepared, harvested and
freeze dried as in Example 1.
These microspheres had an 88% drug incorporation
efficiency with an 11.0% drug load. Microscope analysis
showed that the microsptreres were spherical, generally
smaller and predominantly non-porous. The bulk density of
the microspheres was 0.45 g/mL. The particle size
distribution analysis showed that 50 % of the particles were
below 13.5 ~m (volume distribution), and 80% of the
particles were between 5.8 and 20.0 ~,m. The microspheres
had 107 ppm residual methylene chloride and undetectable
methanol.
Many modifications and variations of the invention
will be apparent to those skilled in the art in light of
the forgoing detailed disclosure. Therefore, within the
scope of the appended claims, the invention can be
practiced otherwise than as specifically shown and
described.
31
